Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl 3-chloro-2-{3-[(2,5-dihydroxy-4-methoxyphenyl)amino]-3-oxopropyl}-4,6-dihydroxybenzoate is a synthetic small molecule belonging to the class of p-hydroxybenzoic acid alkyl esters. It has a molecular formula of C18H18ClNO8 and a molecular weight of approximately 411.8 g/mol[1][2]. The compound is considered experimental and is not approved for clinical use in any country[2]. Its primary known biological activity is as an inhibitor of heat shock protein HSP90-beta (HSP90AB1), suggesting potential utility in modulating protein folding and stress response pathways relevant to cancer or other diseases involving proteostasis[2]. No marketed products or clinical indications are currently associated with this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl 3-chloro-2-{3-[(2,5-dihydroxy-4-methoxyphenyl)amino]-3-oxopropyl}-4,6-dihydroxybenzoate.